Clinical trial NCT03680885: Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness
Official title: Reliability Testing of a Non-invasive, Pain-free, Taste-based Assessment Approach to Lidocaine Effectiveness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: ADHD
Controls
Keywords: Lidocaine ineffectiveness
ADHD
ADD
Lead sponsor: PhenoSolve, LLC
Sponsor class: INDUSTRY
Collaborators: name: Jacobi Medical Center
First posted: 2018-09-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Half the subjects will have a self-reported history of lidocaine working for them (effective) and half will have a history of difficulty getting numb (ineffective).
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This work will assess the reliability of a simple painless test for the effectiveness of the commonly used local anesthetic lidocaine

Detailed description: In prior tests with a convenience sample, subjects who reported that they had no trouble getting numb at the dentist, also got numb with lidocaine gel on the surface of the tongue. That numbness prevented them from being able to taste any flavor until the numbness had worn off. Subjects who reported having trouble getting numb at the dentist, could still taste flavors after the application of lidocaine.

This work will assess the reliability of a taste-based approach for creating a non-invasive way to test lidocaine effectiveness. The controlled trial will assess the ability of lidocaine oral gel to block taste (e.g., sweet) in 20 adults (ages 18-49) half with history of trouble getting numb at the dentist (Arm 2) and half with no trouble (Arm 1). To determine reproducibility, the taste-based test will be done 4 times on different days, twice with lidocaine and twice with a placebo, with randomization and double-blinding. These repeated results will be compared to a fifth assessment, against the "gold standard" of injection of lidocaine, assessed using a dental probe.

On each of four separate visits, in randomized order, the subject will be tested with tastants to the tongue twice after application of a lidocaine gel to the tongue and twice with a placebo gel. After a wait of two-minutes, the three tastants will be tested. The subject is blinded to the taste and the identity of the gel, which have been compounded to look the same.

On the fifth (last) visit, the subject will get an oral injection of lidocaine and the numbness assessed.

The results across the five tests will then be analyzed.

We are testing in separate studies NCT 03563573 and NCT 03676725 the prevalence of lidocaine ineffectiveness in those with Attention Deficit Hyperactivity Disorder (ADHD) and in the general population without ADHD. We believe the prevalence will be higher in ADHD. As a result, in this evaluation we have one Arm "gets numb at the dentist" where exclusion criteria includes ADHD and a second Arm "has trouble getting numb at the dentist" that does not have that exclusion.

Eligibility criteria: Arm 1 Eligibility

Inclusion Criteria:

- Report "get numb at dentist"

Exclusion Criteria:

* ADHD, ADD, and other inattention disorders
* Known adverse reactions to lidocaine;
* Epilepsy
* IQ \<80
* Severe head trauma
* Birth weight \<2270 grams
* Severe autism
* Generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness)
* Mouth sores
* Ehlers Danlos syndrome
* Red hair
* Current pregnancy
* Treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers

Angiotensin Converting Enzyme Inhibitors

* Alacepril (not available in US)
* Benazepril (Lotensin)
* Captopril (trade name Capoten)
* Cilazapril (Inhibace)
* Delapril (not available in US)
* Enalapril (Vasotec/Renitec)
* Fosinopril (Fositen/Monopril)
* Imidapril (Tanatril)
* Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril)
* Moexipril (Univasc)
* Perindopril (Coversyl/Aceon/Perindo)
* Quinapril (Accupril)
* Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace)
* Spirapril (Renormax)
* Temocapril (not available in US)
* Teprotide (but not active by oral administration and not used in US)
* Trandolapril (Mavik/Odrik/Gopten)
* Zofenopril

Angiotensin receptor blockers

* Azilsartan (Edarbi)
* Candesartan (Atacand)
* Eprosartan (Teveten)
* Fimasartan (Kanarb)
* Irbesartan (Avapro)
* Losartan (Cozaar)
* Olmesartan (Benicar/Olmetec)
* Telmisartan (Micardis)
* Valsartan (Diovan)

Aldosterone antagonists

* Spironolactone (Aldactone)
* Eplerenone (Inspra)

Renin inhibitors - Aliskiren (Tekturna, Rasilez)

Other potassium elevating agents

* Antibiotics, including penicillin G and trimethoprim
* Azole antifungals
* Beta-blockers
* Herbal supplements, including milkweed, lily of the valley, Siberian ginseng, Hawthorn berries
* Heparin
* Nonsteroidal anti-inflammatory medications (NSAIDs)
* Oral contraceptives containing drospirenone

Arm 2 Eligibility

Inclusion Criteria:

- Report "trouble getting numb at dentist"

Exclusion Criteria:

* Known adverse reactions to lidocaine;
* Epilepsy
* IQ \<80
* Severe head trauma
* Birth weight \<2270 grams
* Severe autism
* Generalized anxiety disorders (but dental-specific anxiety will not be an exclusion because many of these individuals may be ones with anxiety because of painful dental experiences with lidocaine ineffectiveness)
* Mouth sores
* Ehlers Danlos syndrome
* Red hair
* Current pregnancy
* Treatment currently with potassium or potassium-elevating drugs such as renin-angiotensin-aldosterone blockers

Angiotensin Converting Enzyme Inhibitors

* Alacepril (not available in US)
* Benazepril (Lotensin)
* Captopril (trade name Capoten)
* Cilazapril (Inhibace)
* Delapril (not available in US)
* Enalapril (Vasotec/Renitec)
* Fosinopril (Fositen/Monopril)
* Imidapril (Tanatril)
* Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril)
* Moexipril (Univasc)
* Perindopril (Coversyl/Aceon/Perindo)
* Quinapril (Accupril)
* Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace)
* Spirapril (Renormax)
* Temocapril (not available in US)
* Teprotide (but not active by oral administration and not used in US)
* Trandolapril (Mavik/Odrik/Gopten)
* Zofenopril

Angiotensin receptor blockers

* Azilsartan (Edarbi)
* Candesartan (Atacand)
* Eprosartan (Teveten)
* Fimasartan (Kanarb)
* Irbesartan (Avapro)
* Losartan (Cozaar)
* Olmesartan (Benicar/Olmetec)
* Telmisartan (Micardis)
* Valsartan (Diovan)

Aldosterone antagonists

* Spironolactone (Aldactone)
* Eplerenone (Inspra)

Renin inhibitors

- Aliskiren (Tekturna, Rasilez)

Other potassium elevating agents

* Antibiotics, including penicillin G and trimethoprim
* Azole antifungals
* Beta-blockers
* Herbal supplements, including milkweed, lily of the valley, Siberian ginseng, Hawthorn berries
* Heparin
* Nonsteroidal anti-inflammatory medications (NSAIDs)
* Oral contraceptives containing drospirenone

Primary outcomes:
measure: Taste sensation after lidocaine or placebo
timeFrame: 4 visits each of 30 minutes within weeks of one another, average ~1 month total
measure: Ability to feel pressure and discomfort after injection of lidocaine into the cheek
timeFrame: 1 visit of 30 minutes after other 4 visits, average ~1 month total
Secondary outcomes:
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Jacobi Medical Center
state: New York
Study officials:
affiliation: PhenoSolve, LLC
name: Michael Segal, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Infante MA, Moore EM, Nguyen TT, Fourligas N, Mattson SN, Riley EP. Objective assessment of ADHD core symptoms in children with heavy prenatal alcohol exposure. Physiol Behav. 2015 Sep 1;148:45-50. doi: 10.1016/j.physbeh.2014.10.014. Epub 2014 Oct 23.
citation: Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008 Apr 21;6:18. doi: 10.1186/1479-5876-6-18.
citation: Nakai Y, Milgrom P, Mancl L, Coldwell SE, Domoto PK, Ramsay DS. Effectiveness of local anesthesia in pediatric dental practice. J Am Dent Assoc. 2000 Dec;131(12):1699-705. doi: 10.14219/jada.archive.2000.0115.
citation: Segal MM. We cannot say whether attention deficit hyperactivity disorder exists, but we can find its molecular mechanisms. Pediatr Neurol. 2014 Jul;51(1):15-6. doi: 10.1016/j.pediatrneurol.2014.04.014. Epub 2014 Apr 18. No abstract available.
citation: Segal MM, Rogers GF, Needleman HL, Chapman CA. Hypokalemic sensory overstimulation. J Child Neurol. 2007 Dec;22(12):1408-10. doi: 10.1177/0883073807307095.
citation: Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol. 1997 Jun;77(6):3021-34. doi: 10.1152/jn.1997.77.6.3021.
citation: Teicher MH, Polcari A, Fourligas N, Vitaliano G, Navalta CP. Hyperactivity persists in male and female adults with ADHD and remains a highly discriminative feature of the disorder: a case-control study. BMC Psychiatry. 2012 Nov 7;12:190. doi: 10.1186/1471-244X-12-190.
citation: Mintz M, Badner V, Feldman LK, Mintz P, Saraghi M, Diaz J, Mezhebovsky I, Axelrod I, Gleeson J, Liu C, Smith C, Chow H, Zurakowski D, Segal MM. Lidocaine Ineffectiveness Suggests New Psychopharmacology Drug Target. Psychopharmacol Bull. 2022 Jun 27;52(3):20-30.